CRO Solutions for Metabolic Diseases
Cyagen offers comprehensive CRO solutions to accelerate your research in metabolic diseases. From diverse, validated disease models to robust in vivo and in vitro platforms, we provide end-to-end support, guiding your projects seamlessly from early discovery to IND application. Partner with us to advance your therapeutic breakthroughs.
Integrated CRO Solutions for Metabolic Disease Drug Development
Cyagen provides end-to-end preclinical CRO solutions for metabolic disease research and
therapeutic development. Our capabilities include validated animal models and customized in vivo and
in vitro
studies for obesity, diabetes, dyslipidemia, metabolic dysfunction-associated steatotic liver disease
(MASLD/MASH), and metabolic kidney disorders. From disease model selection and mechanism-of-action studies to
efficacy, pharmacodynamic, and IND-enabling research, our integrated platforms help researchers generate
reliable translational data and advance metabolic drug candidates toward clinical development.
{{static_tabs[0].title}}
Ready-to-Use Metabolic Disease Models
Accelerate metabolic disease research with Cyagen’s in stock animal models and
standardized modeling kits. Our portfolio supports studies in obesity, diabetes, dyslipidemia,
MASLD/MASH, and metabolic kidney disorders, with genetically engineered models, diet-induced models,
and chemically induced disease systems. Researchers can select validated off-the-shelf models for
rapid study initiation or use optimized modeling kits to establish reproducible disease phenotypes
in suitable mouse or rat strains. Cyagen also provides model selection guidance based on the
therapeutic target, mechanism of action, disease stage, and required study endpoints.
Base Strain
Search for Models
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
|
+
|
Next Page
Custom Induction-Based Models
In addition to our genetic model library, Cyagen offers a collection of
induction-based models developed through established experimental protocols. Beyond our standard
MouseAtlas™ catalog, Cyagen offers a robust portfolio of fully validated, induction-based models
exclusively through our custom CRO services.
These models are ideal for studies requiring clinical-like disease phenotypes that cannot be fully
recapitulated by gene-edited lines alone.
Available Models Include
| Related Diseases | Modeling Method | Strain Background |
|---|---|---|
| Obesity and Prediabetes | High-Fat Diet (HFD)-Induced | Mouse & Rat |
| Diet-Induced Obesity (DIO) | Mouse | |
| Type 2 Diabetes | STZ plus HFD-Induced | Mouse |
| Zucker Diabetic Fatty (ZDF) | Rat | |
| Type 1 Diabetes | Streptozotocin (STZ)-Induced | Mouse |
| Sarcopenia | Dexamethasone-Induced | Mouse |
| MASLD and MASH | Diet-Induced Obesity (DIO) | Mouse |
| DIO plus CCl₄-Induced | Mouse | |
| Gubra-Amylin NASH Diet plus CCl₄-Induced | Mouse | |
| Liver Fibrosis | CCl₄-Induced | Mouse |
| Acute Kidney Injury | Acetaminophen (APAP)-Induced | Mouse |
| Polycystic Kidney Disease | Induced | Mouse |
INTEGRATED PRECLINICAL CAPABILITIES
Can't Find Your Model?
If your desired model isn't listed, our experts are here to help!
{{static_tabs[1].title}}
Metabolic Disease Phenotyping and Efficacy Readouts
Our in vivo CRO platform delivers customized efficacy evaluation for
metabolic
drugs. From glucose tolerance and lipid profiling to liver pathology, we help generate data aligned
with clinical endpoints.
Obesity and Diabetes Phenotyping
- Body weight monitoring
- Fasting and random blood glucose measurement
- Metabolic cage analysis
- Assessment of obesity- and diabetes-related metabolic parameters
Metabolic Pharmacology Pilot Studies
- Conditioned taste aversion studies
- Gastric emptying tests
- Acute food intake studies
- Glucose tolerance tests (GTT)
- Insulin tolerance tests (ITT)
Liver and Pancreas Evaluation
- Liver weight and tissue volume quantification
- Serum liver enzyme analysis, including ALT and AST
- Histopathological analysis using H&E, Oil Red O, Sirius Red, and immunohistochemistry
- Assessment of hepatic steatosis, inflammation, and fibrosis
- Evaluation of pancreatic edema and tissue injury
- Observation and quantification of saponification spots in acute pancreatitis models
Kidney Function and Injury Assessment
- Urine volume, protein, and glucose analysis
- Glomerular filtration rate (GFR) assessment
- Blood urea nitrogen (BUN) and serum creatinine measurement
- Renal inflammatory and fibrotic biomarker analysis, including TGF-β1 and IL-6
- Histopathological assessment of renal tissue injury
- Evaluation of kidney function and disease progression using renal injury biomarkers
INTEGRATED PRECLINICAL CAPABILITIES
Looking for tailored in vivo assays to
validate your
candidate?
{{static_tabs[2].title}}
In Vitro Target Validation & Mechanistic Studies
Our in vitro platform supports target validation and mechanism-of-action
studies
for metabolic drug development using disease-relevant cellular models, biochemical assays, and
biomarker profiling.
Target-Based Drug Screening
- PPAR-α/γ activity assays
- 11β-HSD inhibition assays
- GLP-1R functional assays
- DPP-IV activity and inhibition assays
Metabolic Biomarker Profiling
- Adipokines and metabolic hormones, including leptin, GIP, GLP-1, resistin, and ghrelin
- Multiplex cytokine detection using MSD, Luminex, and ELISA
Cellular Models for Mechanism-of-Action Studies
- INS-1 and MIN6 pancreatic β-cell models
- HK-2 renal epithelial cells and mesangial cells
- Primary hepatocytes and adipocyte models
- Glucose transporter uptake and cAMP signaling assays
INTEGRATED PRECLINICAL CAPABILITIES
Need support for in vitro screening or mechanistic insights?
Case Studies
Key advantages
Broad Model Coverage with Clinical Relevance
From classic ob/ob and Apoe KO models to inducible MASH and PAH systems, our platform supports both genetic and induction-based disease models to match diverse drug discovery needs.
Integrated In Vivo & In Vitro Evaluation Systems
Our end-to-end services cover behavioral testing, blood biochemistry, histology, molecular assays, and target engagement studies—empowering complete pharmacodynamic insights in metabolic and cardiovascular indications.
Proven Experience in Translational Research
With 200+ successful projects and validated data for IND-enabling studies, we provide reliable support for preclinical efficacy assessment and customized model development for metabolic and cardiovascular drug pipelines.
Related Resources
Events & Webinars
Special Event MaRS Center 2026
View Details
Promotional Campaign
Shared-Access 300: Fast-Track KO Program
View Details
Blogs & Insights
Is INHBE Only Half of the Activin Story?
View Details
Resource Vault
HUGO-GT™ Models：Efficacy Data & Core Advantages for Small Nucleic Acid Drug Therapeutics
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
